TAEUS Liver System Installed at King’s College Hospital NHS Foundation Trust, Proving ENDRA Life Sciences’ Commitment to Innovation
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer in Thermo Acoustic Enhanced UltraSound (TAEUS), has reached a significant milestone in its quest to revolutionize medical imaging. The company recently announced the installation of its TAEUS liver system at King’s College Hospital NHS Foundation Trust (KCH) in London, a renowned center of excellence within the United Kingdom’s National Health Service (NHS).
KCH will employ ENDRA’s TAEUS liver system in a comprehensive clinical study, aiming to compare its liver fat assessment accuracy with magnetic resonance imaging (MRI), the widely accepted research standard in this field. The arrival of the TAEUS system at KCH is seen as a remarkable development in improving liver fat assessment techniques, potentially leading to more accurate diagnoses and enabling healthcare professionals to devise more personalized treatment plans for patients.
The TAEUS system utilizes novel thermoacoustic technology, which has been protected by ENDRA’s extensive intellectual property (IP) portfolio. The company has recently added three new patents to its collection, further enhancing the IP protection for the TAEUS system. This portfolio now boasts an impressive total of 74 issued patents worldwide, demonstrating ENDRA’s commitment to safeguarding its innovative advancements.
The issuance of new patents in the U.S. China, and Europe reaffirms ENDRA’s position as a global leader in medical imaging. Patent No. 11806113
Comments